Retrospective study of the association between neutering status and changes secondary to degenerative mitral valve disease by Silva, Ana Margarida Ribeiro da
 
 
 
 
 
 
 
 
UNIVERSIDADE DE LISBOA 
Faculdade de Medicina Veterinária 
 
 
 
 
RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN NEUTERING STATUS AND 
CHANGES SECONDARY TO DEGENERATIVE MITRAL VALVE DISEASE 
 
 
 
 
ANA MARGARIDA RIBEIRO DA SILVA 
 
 
 
 
CONSTITUIÇÃO DO JÚRI 
 
 ORIENTADOR 
 
Doutor José Paulo Pacheco Sales Luís 
 
             Doutora Joanna Dukes-McEwan  
 
Doutora Luísa Maria Freire Leal Mateus   
CO-ORIENTADOR 
Doutor Rodolfo Assis Oliveira Leal       Doutor Rodolfo Oliveira Leal 
 
 
2019 
LISBOA 
 
 
 
 
  
 
 
 
 
 
 
 
 
UNIVERSIDADE DE LISBOA 
Faculdade de Medicina Veterinária 
 
 
 
 
RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN NEUTERING STATUS AND 
CHANGES SECONDARY TO DEGENERATIVE MITRAL VALVE DISEASE 
 
 
DISSERTAÇÃO DE MESTRADO INTEGRADO DE MEDICINA VETERINÁRIA 
 
 
ANA MARGARIDA RIBEIRO DA SILVA 
 
 
 
CONSTITUIÇÃO DO JÚRI 
 
 ORIENTADOR 
 
Doutor José Paulo Pacheco Sales Luís 
 
             Doutora Joanna Dukes-McEwan  
 
Doutora Luísa Maria Freire Leal Mateus   
CO-ORIENTADOR 
Doutor Rodolfo Assis Oliveira Leal       Doutor Rodolfo Oliveira Leal 
 
 
 
2019 
LISBOA
 
i 
ACKNOWLEDGEMENTS 
 
O meu primeiro agradecimento é dirigido aos meus pais por todo o apoio que sempre me 
deram e por me tornarem na pessoa que sou hoje. Sem vocês eu não teria chegado aqui. 
Aos meus amigos que estiveram sempre lá para mim durante todos estes anos. À Joana 
Bastos, João Mendes, Gonçalo Reis, Sandrine Silva, Miguel Serra, Inês Pinto e Mariana 
Abreu. Obrigada por todos os momentos e por serem tão espetaculares! Este percurso não 
teria sido o mesmo sem vocês. 
Ao Chico, por estar sempre do meu lado, por me ajudar a acreditar em mim mesma e, 
sobretudo, pela paciência para me aturar. 
À VETuna e ao 55 por serem a minha segunda família e a minha maior alegria nesta 
faculdade. Nunca vos esquecerei. Aos meus queridos estandartes, obrigada por todo o amor 
e dedicação que partilharam comigo, e por nos terem dado o prémio antes de eu sair desta 
casa. Foi a melhor prenda que me podiam ter dado. 
Ao GOTA FMV-ULisboa que me ensinou a crescer e que me deu amigos para a vida. 
A todos aqueles que me acompanharam nas noites intermináveis no Santa Maria e na Cantina 
Velha, obrigada por terem tornado as épocas de exame suportáveis e por me ajudarem a não 
desistir. 
Ao meu co-orientador, Professor Rodolfo Leal, por todo o apoio que me deu e por tudo o que 
me ensinou. 
I would also like to thank Jo, my supervisor and mentor that gave me this wonderful opportunity 
to join the Liverpool cardio team. To Liz, thank you for all the support you gave me and for 
being such a role model! This thesis wouldn’t have happened without your help. 
To all the Liverpool cardio team, Hannah, Fabio, Julie, Sid, Cat, Vicky and Nikki. Thank you 
for all your kindness and for being wonderful teachers. You always made me feel like part of 
the team and I couldn’t be more grateful to you guys. 
To Marie-Suzanne and Ivo, for being my Erasmus family and my partners in crime. Thank you 
for making this experience unforgettable and for being such good friends. I’m sure we will meet 
again!  
ii 
ABSTRACT 
 
Retrospective study of the association between neutering status and changes 
secondary to degenerative mitral valve disease 
 
Myxomatous mitral valve disease is the most common cardiovascular disease reported in 
dogs. Although many patients may remain asymptomatic, some of them progress to left-sided 
congestive heart failure and develop clinical signs. Little has yet been published regarding the 
possible influence of the neutering status on changes secondary to myxomatous mitral valve 
disease. This study aims to assess a possible correlation between neutering status and 
myxomatous mitral valve disease. 
A retrospective study was conducted and included all the cases diagnosed with myxomatous 
mitral valve disease, consulted at the Cardiology service of the University of Liverpool. To help 
assess the association between neutering status and cardiac remodelling, dogs were 
categorized into four groups: FE (female entire), FN (female neutered), ME (male entire) and 
MN (male neutered). 
Retrospective review of echocardiographic data, signalment, and underlying diseases were 
performed. Echocardiographic measurements were made through offline analysis. 
Echocardiographic measurements were then compared between groups. 
Five hundred and eighty-two dogs (n = 582) were included: female entire (n = 24), female 
neutered (n = 235), male entire (n = 115) and male neutered (n = 208). 
Left ventricular internal diameter at end diastole (LVIDd), left atrial dimension to the aortic root 
diameter (LA:Ao) and left atrium maximal dimension to the aortic root dimension (LAmax:Ao) 
were significantly different between ME and MN, with ME dogs presenting higher mean values 
for LVIDd and higher median LA:Ao and LAmax:Ao measurements. Left ventricular internal 
diameter at end systole (LVIDs) was not significantly different between ME and MN. There 
were no significant differences between FE and FN groups. 
This study shows that neutering status may influence the development of myxomatous mitral 
valve disease in male dogs and that entire male dogs could be at higher risk of developing 
cardiac remodelling secondary to myxomatous mitral valve disease. On the other hand, 
neutering status doesn’t seem to have an influence on disease progression in female dogs. 
 
Keywords: degenerative myxomatous mitral valve disease, dog, cardiac remodelling, 
echocardiography, neutering 
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RESUMO 
 
Estudo retrospetivo da associação entre a esterilização e alterações secundárias à 
doença mixomatosa da válvula mitral 
 
A doença mixomatosa da válvula mitral é a doença cardiovascular mais prevalente em cães. 
Apesar da maior parte dos pacientes permanecerem assintomáticos, alguns podem progredir 
para insuficiência cardíaca esquerda e desenvolver sinais clínicos. Até hoje, existem poucas 
publicações sobre o possível efeito que a esterilização possa ter no desenvolvimento da 
doença mixomatosa da válvula mitral. O objetivo deste estudo é avaliar se existe de facto uma 
relação entre a esterilização e a doença mixomatosa da válvula mitral. 
Foi realizado um estudo retrospetivo que incluiu todos os casos diagnosticados com doença 
mixomatosa da válvula mitral consultados no serviço de Cardiologia da Universidade de 
Liverpool. Para avaliar a relação entre a esterilização e a presença de remodelação cardíaca, 
os cães foram categorizados em quatro grupos: FE (fêmeas inteiras), FN (fêmeas 
esterilizadas), ME (machos inteiros) e MN (machos castrados). 
A história pregressa e os dados ecocardiográficos dos animais foram revistos 
retrospetivamente e as medidas ecocardiográficas foram obtidas por medição offline. Estas 
medições foram depois comparadas entre os diferentes grupos. 
Quinhentos e oitenta e dois cães (n = 582) foram incluídos: fêmeas inteiras (n = 24), fêmeas 
esterilizadas (n = 235), machos inteiros (n = 115) e machos castrados (n = 208). 
Nos resultados obtidos, o diâmetro interno do ventrículo esquerdo no final da diástole (LVIDd), 
o rácio átrio esquerdo-aorta (LA:Ao) e o rácio diâmetro máximo do átrio esquerdo-aorta 
(LAmax:Ao) foram estatisticamente significativos entre machos inteiros e machos castrados. 
Os machos inteiros apresentaram não só um LVIDd médio superior, como também uma 
mediana de LA:Ao e LAmax:Ao superior aos machos castrados. 
Ao mesmo tempo, o diâmetro interno do ventrículo esquerdo no final da sístole (LVIDs) não 
mostrou ser estatisticamente significativo entre machos inteiros e machos castrados e 
nenhum dos parâmetros ecocardiográficos anteriormente referidos revelou ser 
estatisticamente significativo entre fêmeas inteiras e fêmeas esterilizadas. 
Este estudo demonstra que a esterilização poderá influenciar o desenvolvimento da doença 
mixomatosa da válvula mitral e que os cães machos inteiros poderão apresentar um maior 
risco de desenvolver remodelação cardíaca secundária a esta doença. No entanto, a 
esterilização não aparenta influenciar a progressão desta doença em cadelas. 
 
Palavras-chave: doença mixomatosa da válvula mitral, cão, remodelação cardíaca, 
ecocardiografia, esterilização   
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I INTRODUCTION 
 
Myxomatous mitral valve disease (MMVD) is the most common cardiovascular disease 
reported in dogs and a high prevalence of this disease has been reported among dogs 
attending primary-care practices in England (Sisson et al., 1999; Mattin et al., 2015). It is 
characterized by progressive degenerative lesions of the left atrioventricular valve complex, 
including the valve annulus, leaflets, chordae tendineae and papillary muscles. This 
myxomatous degeneration often results in mitral regurgitation, causing an increased volume 
load on the left side of the heart (Kogure, 1980; Boswood et al., 2016). 
The disease is known to primarily affect small breed dogs, with Cavalier King Charles spaniels 
being the most prevalent breed (Pedersen, Lorentzen, & Kristensen, 1999). Although the 
prevalence seems to be much lower in larger breeds, these dogs may also develop mitral valve 
disease (Mattin et al., 2015). It has also been reported that males tend to develop this disease 
at a younger age compared with females (Fox, 2012). Although some animals end up 
developing left-sided congestive heart failure, most of the dogs will remain asymptomatic 
throughout their lives (Borgarelli & Haggstrom, 2010). 
Standard transthoracic echocardiographic examination is currently the method of choice for 
visualization and diagnosis of the mitral valve lesions and degree of cardiac remodelling. 
Nevertheless, other diagnostic tools are also recommended in order to assess the 
hemodynamic significance of the disease, such as thoracic radiographs and blood pressure 
measurements (Chetboul & Tissier, 2012; Keene et al., 2019). 
Guidelines have been published, providing a form of categorization of patients according to 
the course of their degenerative mitral valve disease and presence of cardiac enlargement. 
These guidelines are commonly used as a classification method that aids clinicians in 
therapeutic decisions and prognosis (Keene et al., 2019) 
The physiopathology of valvular degeneration in dogs is yet not fully understood (Fox, 2012). 
Nonetheless, neuroendocrine regulation seems to play an important role in the progression of 
the disease (Orton, Lacerda, & MacLea, 2012). Although many risk factors have been 
identified (Mattin et al., 2015) there are currently no publications regarding the possible effects 
that neutering status could have on the development of mitral valve disease. Thus, the aim of 
this study is to determine if there is, in fact, an association between the neutering status and 
cardiac changes secondary to mitral valve degeneration in female and male dogs. 
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II BIBLIOGRAPHIC REVIEW 
 
1. MYXOMATOUS MITRAL VALVE DISEASE 
 
1.1 - THE NORMAL MITRAL VALVE COMPLEX 
The mitral valve complex includes several components: the posterior left atrial wall, the mitral 
valve annulus, the mitral valve leaflets, chordae tendineae, the left ventricular papillary 
muscles and associated left ventricular wall (Fox, 2012). During diastole, the blood in the left 
atrium flows through the mitral valve and into the left ventricle, while during systole, the 
contraction of the left ventricle allows the ejection of blood through the aorta. Normally in 
systole, the atrioventricular valves remain closed, allowing a direct blood flow from the ventricle 
into the aorta, without regurgitation (Lincoln, Lange & Yutzey, 2006; Vlaming et al., 2015). 
The mitral valve comprises the anterior or septal leaflet and the posterior or parietal leaflet. 
These two leaflets are supported by the chordae tendineae that insert into the papillary 
muscles. All of these structures help prevent mitral valve prolapse and regurgitation (Lincoln 
et al., 2006; Fox, 2012). Normally, the mitral valve leaflets appear as thin, translucent 
structures, without any nodules or thickening of the valve’s margins (Fox, 2012). 
Chordae tendineae are fibrous chords, and can be classified as first-order chordae, which are 
thin and anchor the free edges of the leaflets to the papillary muscles; second-order chordae, 
which are larger than the previous ones, arise from the papillary muscles and insert beyond in 
the midventricular surface of the leaflets; and finally, the third-order chordae, that arise from 
the ventricular wall and insert similarly to second-order chordae. Third-order chordae 
tendineae are uncommonly found in dogs (François et al., 2007; Fox, 2012). 
Histologically, the mitral valve has four distinct layers, from the atrial to the ventricular aspect: 
the atrialis, the spongiosa, the fibrosa and the ventricularis (Lincoln et al., 2006; Fox, 2012; 
Orton et al., 2012). The atrialis is composed of a thin layer of endothelial cells overlying elastic 
fibres, collagen fibres and smooth muscle cells. The spongiosa consists of loose collagen 
fibres and is rich in proteoglycans and glycosaminoglycans. The fibrosa is formed by densely 
organized collagen bundles, that help countering the tensile forces placed on the closed valve. 
This fibrosa layer branches off to form the central core of the chordae tendineae. The 
ventricularis is the thin layer on the ventricular side, similar to the atrialis, except that it does 
not have smooth muscle cells (Fox, 2012; Orton et al., 2012; Markby, Summers, MacRae, Del-
Pozo, & Corcoran, 2017). 
The cellular component of the heart valves is composed predominantly of two major cellular 
types: the valve endothelial cells (VEC) and the valve interstitial cells (VIC). Both these cells 
are believed to help maintain valve homeostasis (Aupperle & Disatian, 2012). The VECs form 
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a single cell layer that covers the surface of both leaflets’ sides. This layer functions as a barrier 
between the valve leaflets and the blood (Aupperle & Disatian, 2012; Orton et al., 2012). 
Valve interstitial cells are the most common cells in the heart valves and they can be found 
scattered throughout the atrialis, spongiosa and fibrosa layers (Liu, Joag, & Gotlieb, 2007; 
Markby et al., 2017). They are thought to have a major role in the maintenance of the 
extracellular matrix, through continuous production and degradation of the matrix components, 
preserving the normal valve structure and function (Aupperle & Disatian, 2012; Orton et al., 
2012). Given that myxomatous mitral valve disease is primarily a dysregulation of the 
extracellular matrix, these cells are believed to play an important role in the pathogenesis of 
the disease (Orton et al., 2012). Moreover, it seems that VICs undergo a phenotypic 
transformation in diseased valves, which corroborates their importance in the genesis of mitral 
valve degeneration (Liu et al., 2007). 
 
1.2 – MACROSCOPIC LESIONS AND CLASSIFICATION 
The predominant feature of MMVD is the nodular thickening and deformation of the valve 
leaflets, that result in mitral insufficiency (Kogure, 1980). Lesions typically occur in the mitral 
or left atrioventricular valve, however, sometimes lesions can be seen in the tricuspid valve. 
The aortic and pulmonary valve are rarely affected. Nevertheless, lesions in the mitral valve 
have the greatest frequency and severity (Whitney, 1974). 
Early valvular changes are mostly found on the free edge of the valve leaflet, particularly where 
the first-order chordae tendineae attach (Corcoran et al., 2004; Fox, 2012). The normal thin 
translucent leaflets become opaque and thickened. With disease progression, they begin to 
exhibit a more diffuse valve nodularity and deformation (Fox, 2012). In advanced cases, the 
chordae tendineae are also affected, with thickening and shortening of the chordae that can 
later result in their rupture (Detweiler, Patterson, Hubben, & Botts, 1961; Corcoran et al., 2004). 
The marked deformity of the valve allows the leaflets to bulge convexly towards the atrium, 
resulting in mitral valve prolapse (Detweiler et al., 1961; Fox, 2012). 
The macroscopic lesions secondary to MMVD can be described according to the Whitney 
(1974) classification system: 
Type I lesions: a few small oedematous nodules can be found on the free edge of the valve 
leaflets. Chordae tendineae are unaffected and there is no valvular incompetence during this 
stage. 
Type II lesions: the oedematous nodules become larger and more numerous and they may 
exhibit a greyish-white colour. Some nodules may start to coalesce with the surrounding 
nodules. Chordae tendineae remain unaffected during this stage and there is no valvular 
incompetence. 
Type III lesions: the greyish-white nodules become even larger and plaque-like elevations can 
also be seen. The chordae tendineae are now affected and they appear thickened and irregular 
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in their proximal portion, near their insertion in the valve leaflets. There can be evidence of 
valvular incompetence. 
Type IV lesions: there are large greyish-white nodules and plaque-like elevations that result in 
severe distortion and thickening of the valve. The chordae tendineae appear thickened and 
irregular, and some may even be ruptured. Most cases present valvular incompetence. 
These grades are strongly associated with advancing age and intensity of cardiac murmurs 
(Han, Black, Culshaw, French, & Corcoran, 2010).  
 
1.3 – HISTOPATHOLOGIC FEATURES 
Histopathologic changes in MMVD assume a focal distribution (Han et al., 2008). As expected, 
changes occur mainly in the free edge of the leaflets, although some changes can also be 
seen towards the midzone. The base typically remains unaffected. Both the anterior and 
posterior leaflets appear to be altered. However, the posterior leaflet is usually slightly thicker 
than the anterior one. (Han et al., 2010; Markby et al., 2017). 
The most prominent microscopic feature in myxomatous degeneration is the destruction of 
collagen bundles and deposition of glycosaminoglycans (Kogure, 1980). The connective tissue 
of the fibrosa layer becomes markedly disorganized, with reduction of the collagen density and 
alterations in fibril alignment. This decrease in collagen seems to gradually progress with the 
disease (Han et al., 2010). There is also a progressive expansion of the spongiosa, with 
accumulation of glycosaminoglycans and proliferation of oedematous ground substance within 
the layer. The expansion of the spongiosa eventually results in the thickness of the valve (Han 
et al., 2010; Fox, 2012). 
The lesions assume a patchy distribution and, in more advanced cases, there is a loss of 
distinction between the fibrosa and spongiosa layers (Corcoran et al., 2004; Fox, 2012). 
Myxomatous areas also have fewer cells than normal valve tissue. However, cell numbers 
seem to remain constant throughout the disease progression, while the remaining cells seem 
to become more elongated (Han et al., 2010). Myxomatous degeneration can also affect 
chordae tendineae, which may lead to chordal rupture (Corcoran et al., 2004; Fox, 2012). 
Valvular interstitial cells are believed to play an important role in the pathophysiology of MMVD 
(Han et al., 2008). VICs exist in their quiescent form in the adult valve and are believed to 
undergo a phenotypic transformation and become activated in response to valve injury and 
disease (Liu et al., 2007; Markby et al., 2017). It does seem that quiescent cells predominate 
in the mitral valves of clinically normal dogs, while valves with myxomatous degeneration suffer 
an increase in the activated VICs population (Han et al., 2008). Activated cells are involved in 
extracellular remodelling, and they can be found among the areas of loose collagen bundles. 
The activation of quiescent VICs is associated with an increase in secretion of extracellular 
matrix. It is believed that this phenotypic alteration accounts for the alterations in the 
extracellular matrix that are found in MMVD (Han et al., 2008; Markby et al., 2017). 
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Valve leaflets alterations also include endothelial damage (Fox, 2012). Scanning electron 
microscopy has revealed areas of endothelial loss and increase of surface microappendages. 
These areas of endothelial injury seem to be more prominent at the valve’s free edge, both on 
the ventricular and atrial side. Platelets have also be found adhered to areas of endothelial 
damage (Corcoran et al., 2004). 
It has been speculated that platelets could adhere to the damaged endothelium in affected 
valves, and release a serotonin signal which could potentially lead to the activation of the 
quiescent VICs (Han et al., 2008). Indeed, in vitro models have shown that VICs can migrate 
and proliferate in response to endothelial injury. (Lester, Damji, Tanaka, & Gedeon, 1992). 
Furthermore, adhesion molecules are upregulated in MMVD. Injured endothelial cells can 
express these adhesion molecules, which might facilitate platelet adhesion (Oyama & Chittur, 
2006). These findings seem to support the theory that serotonin release in response to a 
primary injury of unknown aetiology might act as a perpetuating mechanism for MMVD (Oyama 
& Levy, 2010; Orton et al., 2012). Nevertheless, more studies are needed to determine the 
primary cause of this valve injury.  
 
1.4 – MITRAL REGURGITATION AND CARDIAC REMODELLING 
The degenerative changes that occur in the mitral valve are responsible for mitral regurgitation, 
which can lead to congestive heart failure (Richards, Farrar, Kornreich, Moise, & Butcher, 
2012). The valve becomes weakened by the degeneration of the collagen bundles, resulting 
in mechanical failure of the valve (Kogure, 1980; Markby et al., 2017). Additionally, chordal 
elongation and rupture also contribute to valvular insufficiency (Fox, 2012). 
The deformation of the valve structure that occurs with MMVD, combined with the elongation 
of the chordae tendineae, contribute to reduced coaptation, which in turn results in mitral 
regurgitation (Richards et al., 2012). Regurgitation volume is influenced by the severity of the 
valve damage, the integrity of the chordae tendineae, and the degree of left atrial dilation, 
annular dilation and ventricular dilation (Sisson, Kvart, & Darke, 1999). 
Valvular regurgitation can lead to left ventricular volume overload, inducing ventricular 
remodelling with eccentric hypertrophy (Keene et al., 2019). In eccentric hypertrophy, the left 
ventricular lumen appears dilated, while the left ventricular free wall is either normal or slightly 
thickened (Sisson, Kvart, & Darke, 1999). This volume overload contributes to the increase in 
cardiomyocyte length. Remodelling of the cardiomyocytes can also result in left atrial dilation 
and this can eventually culminate in left-sided congestive heart failure (Lord, Hansson, Kvart, 
& Haggstrom, 2010). 
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1.5 – CARDIOVASCULAR SEQUALAE SECONDARY TO MYXOMATOUS MITRAL 
VALVE DISEASE 
Firstly, the most important consequence of MMVD is heart failure. Heart failure can be 
described as a clinical syndrome that can be caused by multiple heart diseases, such as 
MMVD (Keene et al., 2019). When there is a sufficient rise in the left atrial pressure, pulmonary 
congestion develops, accompanied with left-sided congestive heart failure (Sisson et al., 
1999).  Impaired cardiac function can result in increased venous and capillary pressures, which 
cause congestion and oedema (Hamlin, 1999). 
MMVD is also an important cause of pulmonary hypertension (Kellihan & Stepien, 2012). A 
previous study with 54 dogs reported that 41% of cases of pulmonary hypertension were due 
to MMVD (Pyle, Abbott, & Maclean, 2004). An increase in left atrial pressure is responsible for 
the development of pulmonary hypertension, and pulmonary hypertension is in the continuum 
of progression of heart disease to heart failure (Stepien, 2009; Kellihan & Stepien, 2012). 
The severity of pulmonary hypertension increases with the progression of MMVD. In more 
advanced cases the increased pulmonary pressure may induce right ventricular hypertrophy 
and right atrial dilation, culminating in right-sided heart failure (Pyle et al., 2004; Serres et al., 
2006; Kellihan & Stepien, 2012). Nevertheless, mild pulmonary hypertension is identified in 
most dogs with severe MMVD (Serres et al., 2006). Echocardiographic imaging is the most 
common, non-invasive method used to diagnose pulmonary hypertension (Kellihan & Stepien, 
2012). 
It has been well described that MMVD can affect chordae tendineae and, in more advanced 
cases, can lead to chordal rupture (Whitney, 1974). A previous study reported that from a 
population of 114 dogs with MMVD, 16% presented with chordal rupture, and 90% of the dogs 
with ruptured chordae had severe regurgitation jets assessed by colour Doppler 
echocardiography (François et al., 2007). Rupture most commonly affects first-order chordae 
and they usually occur in the proximal third of the chordae, close to their insertion to the valve’s 
leaflets (Fox, 2012). Clinical signs associated with the rupture of first-order chordae are usually 
more severe, particularly with the first-order chordae of the anterior mitral valve leaflet. Rupture 
of second or third-order chordae may result in minimal or no clinical signs (Sisson et. al., 1999). 
Chordal rupture can lead to acute heart failure with associated pulmonary oedema and 
respiratory distress (Yun, Niczyporuk, Sarris, Fann, & Miller, 1991; Sisson et al., 1999; 
François et al., 2007). Nevertheless, chordal rupture can also be identified in asymptomatic 
patients with MMVD through echocardiographic examination. Some of these dogs may even 
show no signs of cardiac enlargement, despite their marked mitral valve regurgitation (François 
et al., 2007). 
Lastly, left atrial endocardial tear is another possible, though uncommon, complication of 
MMVD (Sisson et al., 1999). The high-velocity jets of mitral regurgitation can sometimes 
traumatize the left atrial endocardium, inflicting focal endocardial lesions, which can eventually 
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perforate (Fox, 2012). This complication seems to be more prevalent in male dogs (Buchanan, 
1972). Atrial tears can range from non-perforating atrial tears to perforated left atrium with 
hemopericardium. Non-perforating atrial tears seem to be the most prevalent type (Buchanan, 
1972; Fox, 2012). 
 
1.6 – ACTIVATION OF NEUROHORMONAL PATHWAYS AND HEART FAILURE  
Heart failure is the outcome of a cascade of events that involves activation of the sympathetic 
system and of the renin-angiotensin-aldosterone system (RAAS) (Hasenfu, 1998). In MMVD, 
mitral regurgitation often leads to a decrease in cardiac output. Decreased cardiac output leads 
to a reduction in systemic arterial pressure. This reduction stimulates the baroreceptors located 
in the aorta and carotid sinus, which in turn promote generalized sympathetic stimulation 
(Hamlin, 1999; Sisson, 2004). The elevated sympathetic system increases heart rate and 
promotes constriction of arterioles and veins (Hamlin, 1999). 
The reduction in cardiac output also leads to a reduction in the renal blood flow and stimulation 
of the kidney’s juxtaglomerular apparatus. This stimulation promotes the activation of RAAS 
via the release of renin. Activation of RAAS culminates with the conversion of angiotensin II, 
which is responsible for multiple events, such as: the constriction of arteries, arterioles and 
veins; the release of the antidiuretic hormone vasopressin; the increase of water consumption 
and production of aldosterone (Hamlin, 1999). Vasopressin and aldosterone result in sodium 
and water retention, leading to the development of oedema (Riegger & Liebau, 1982; Hamlin, 
1999). 
Elevation of angiotensin II and sympathetic system activation are important in the restoration 
of arterial blood pressure in the early stages of the disease, but heightened neurohormonal 
activity may eventually lead to heart failure (Cant et al., 2008). Venous constriction helps to 
increase the venous return or preload, increasing cardiac output, but the resulting high venous 
and capillary pressures can culminate in the development of congestion. Angiotensin II and 
aldosterone induce detrimental ventricular remodelling processes, that further accelerates 
clinical deterioration (Sisson, 2004). Vasopressin and aldosterone also contribute to the 
development of ascites and pulmonary oedema (Hamlin, 1999). 
In response to the increasing effects of the RAAS in heart diseases, there is an increased 
production of natriuretic peptides. Natriuretic peptides are produced in response to myocardial 
overload and they antagonize RAAS’ effects: by promoting natriuresis, diuresis, blood flow in 
the kidneys and vasodilation; and by increasing the heart’s diastolic function (Lima & Ferreira, 
2017). Natriuretic peptides are hormones that are synthetized essentially by the 
cardiomyocytes in response to cardiac wall stretch. These include the atrial natriuretic peptide 
(ANP) and the brain natriuretic peptide (BNP) (Biondo et al., 2003). 
ANP and BNP are produced as peptide sequences, pro-ANP and pro-BNP, which are stored 
in membrane-bound granules. Pro-ANP is produced in the atria, while pro-BNP is mainly 
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formed in the ventricles, but can also be produced in the atria. (Sisson, 2004; Chetboul et al., 
2009). These are later cleaved into the circulating biologically active forms, ANP and BNP, and 
into the inactive ones, the amino-terminal fragments, also termed NT-proANP and NT-proBNP. 
Both active and inactive molecules are released into the circulation. A sudden rise in ANP and 
BNP plasma levels occurs secondary to their release from the storage granules, in response 
to cardiac wall stress (Sisson, 2004). ANP (and NT-proANP) increases secondary to atrial wall 
stress, while BNP’s (and NT-proBNP’s) plasma levels rise chiefly due to ventricular dysfunction 
and dilation (Haggstrom et al., 2000). A previous study demonstrated that ANP and BNP’s 
plasma levels were higher in dogs with experimental mitral regurgitation and also that plasma 
levels were higher in dogs with heart failure than in dogs with subclinical disease (Asano, 
Masuda, Okumura, Kadosawa, & Fujinaga, 1999). Thus, natriuretic peptides have gained 
importance as cardiac biomarkers, aiding both in the diagnosis and monitoring of heart 
diseases (Lima & Ferreira, 2017). 
 
1.7 – CLASSIFICATION OF HEART DISEASE AND HEART FAILURE 
The American College of Veterinary Internal Medicine (ACVIM) adapted the American Heart 
Association classification system for the treatment of heart disease and failure in humans to 
canine MMVD (Keene et al., 2019). In this statement, they propose the following classification 
system: 
Stage A: dogs at high-risk of developing MMVD - like Cavalier King Charles spaniels (CKCS) 
and other predisposed breeds - that still have not developed any cardiac remodelling or mitral 
regurgitation; 
Stage B1: asymptomatic dogs with heart disease that still present no echocardiographic or 
radiographic evidence of cardiac remodelling, and also the ones who present cardiac 
remodelling, but still do not meet the criteria outlined below; 
Stage B2: asymptomatic patients that have severe hemodynamic mitral regurgitation, which 
can be evidenced by echocardiographic and radiographic findings of left-sided heart 
enlargement that meet the following criteria: 
1. Murmur intensity III/VI or bigger; 
2. Echocardiographic left atrial dimension to the aortic root dimension (LA:Ao) ratio ≥ 
1.6, which should be measured in the right-sided short axis view in early diastole; 
3. Left ventricular internal diameter in early diastole (LVIDd) ≥ 1.7, which is normalized 
for body weight;  
4. Radiographic vertebral heart score ≥ 10.5; 
The presented criteria were elaborated to help clinicians on the identification of dogs that 
should start medical treatment in order to delay the onset of heart failure; 
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Stage C: dogs with past or current clinical signs of congestive heart failure. This stage can be 
further differentiated between dogs with acute heart failure that require hospital care and dogs 
with heart failure that can be managed as outpatients; 
Stage D: patients with heart failure refractory to standard treatment. As with stage C, this stage 
can be further differentiated between dogs in need of hospital care and dogs that can be 
treated on an outpatient basis. 
 
2. SIGNALMENT 
Myxomatous mitral valve disease is the most common cardiovascular disease found in the 
canine population, representing 75% of all cardiovascular diseases in this species (Detweiler 
& Patterson, 1965). It is also the main cause of left apical systolic murmurs in small-breed dogs 
(Serfass et al., 2006). 
It has been well established that the prevalence and severity of the disease increase with age 
(Pedersen et al., 1999; Pedersen & Haggstrom, 2000). MMVD is rarely found in dogs less than 
5 years of age (Whitney, 1974), except in Cavalier King Charles spaniels (CKCS), in which the 
disease can appear at younger ages (Chetboul et al., 2004). Indeed CKCS have a much higher 
predisposition to MMVD compared with other breeds and MMVD seems to have a polygenic 
inheritance in this breed ( Swenson, Haggstrom, Kvart, & Juneja, 1996; Pedersen et al., 1999; 
Serfass et al., 2006). In one study, that included a population of 451 CKCS, the prevalence of 
the disease reached 100% in dogs over 11 years of age (Chetboul et al., 2004). Hence, CKCS 
are considered to be particularly at risk of developing MMVD (Serfass et al., 2006). 
Other breeds also seem to be predisposed, such as Dachshunds, miniature and toy Poodles, 
Yorkshire terriers, Chihuahuas and Shih Tzus (Serfass et al., 2006; Borgarelli et al., 2012; 
Mattin et al., 2015; Keene et al., 2019). The disease also seems to be inherited in Dachshunds 
(Olsen, Fredholm, & Pedersen, 1999). Overall, MMVD affects primarily small-breed dogs and 
less commonly larger breeds. German Shepherd dogs seem to be over-represented among 
large-breeds (Borgarelli et al., 2004; Borgarelli et al., 2012). 
Even though both genders may develop MMVD, male dogs seem to develop the disease at 
younger ages, which means that at a given age the prevalence is higher in males than in 
females (Egenvall, Bonnett, & Haggstrom, 2006; Ljungvall & Haggstrom, 2017). Moreover, a 
previous study that analysed the prevalence of MMVD in dogs attending primary-care practices 
in England reported that MMVD was more prevalent in dogs compared to bitches (Mattin et 
al., 2015). 
 
3. HISTORY, CLINICAL SIGNS AND PHYSICAL EXAMINATION 
Mitral regurgitation results in a left-apical systolic murmur, and this is the most important clinical 
manifestation in dogs with MMVD (Haggstrom, Kvart, & Hansson, 1995; Serfass et al., 2006; 
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Borgarelli et al., 2012). The clinician can suspect MMVD when this auscultatory finding is found 
in a dog with typical signalment (Borgarelli & Haggstrom, 2010). The intensity of the heart 
murmur seems to increase with the severity of the disease and with the age of the patient 
(Haggstrom et al., 1995; Serfass et al., 2006). However, large breed dogs affected with MMVD 
seem to have less intense murmurs compared with small breed dogs (Borgarelli et al., 2004).  
The clinical presentation of dogs with MMVD can be rather variable. Some patients may remain 
asymptomatic throughout their lives, while others may develop signs of pulmonary oedema 
(Borgarelli & Haggstrom, 2010). Patients with MMVD may also exhibit cough (Borgarelli et al., 
2012). Cough has been thought to be a sign of developing congestive heart failure in dogs. 
However, patients with pulmonary oedema should have a significant amount of fluid flooding 
the upper airways in order to develop a cough, which is generally described as a moist cough 
(Ware & Bonagura, 1999; Ferasin, Crews, Biller, Lamb, & Borgarelli, 2013). Therefore, 
coughing is now believed to be primarily caused by cardiomegaly and, particularly, left atrial 
enlargement. It is thought that left atrial enlargement may cause mechanical compression of 
both the trachea and mainstem bronchi, leading to the stimulation of cough receptors (Ferasin 
et al., 2013; Ferasin & Linney, 2019). Coughing dogs with MMVD can show radiographic signs 
of compression of the left mainstem bronchus by the dilated left atrium, which is consistent 
with the previous statement. Nevertheless, it is important to note that old, small-breed dogs, 
which are more commonly affected by MMVD are also predisposed to respiratory disorders 
that may lead to coughing, such as chronic bronchitis and tracheal collapse. Thus, in some 
cases, coughing may be of both cardiac and respiratory origin (Guglielmini, Diana, Pietra, Di 
Tommaso, & Cipone, 2009). 
Patients can also present with a history of syncope and progressive exercise intolerance, 
especially when left ventricular output is impaired. When patients progress to left-sided 
congestive heart failure, they start exhibiting clinical signs of respiratory distress due to 
pulmonary oedema, such as dyspnoea and tachypnoea (Armstrong, Terrance, Stopps, Ford, 
& De Bold, 1986; Sisson et al., 1999; Kellihan & Stepien, 2012). A previous study characterized 
the sleeping respiratory rates of 190 dogs with subclinical left-sided heart disease. The results 
of this study suggest that in patients with subclinical heart disease, their sleeping respiratory 
rate should be equal or lower than 25 breaths/minute. A persistent sleeping respiratory rate of 
30 breaths/minute or higher may indicate that the patient is progressing to left-sided heart 
failure and further investigations should be pursued. The authors recommend the use of this 
parameter as a means of helping owners to monitor patients at home (Ohad, Rishniw, 
Ljungvall, Porciello, & Haggstrom, 2013). When patients develop right-sided CHF secondary 
to pulmonary hypertension, they can also exhibit ascites and pleural effusion (Chetboul et al., 
2009). 
A previous study reported that several dogs without an audible murmur had mild mitral 
regurgitation secondary to MMVD, assessed by echocardiographic examination. This is 
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probably because minimal leakages may not be capable of inducing audible murmurs. 
Therefore, it is important to point out that the lack of an audible murmur cannot rule out mild 
mitral regurgitation (Ljungvall et al., 2009). Furthermore, these results seem to be in agreement 
with a previous study, which suggests that echocardiography is a more sensitive method of 
diagnosing dogs with very mild MMVD (Borgarelli et al., 2012). 
 
4. DIAGNOSTIC TESTING 
 
4.1– CARDIAC BIOMARKERS 
A biological marker, or biomarker, can be described as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” (Atkinson et al., 2001, 
p. 91). Biomarkers can then be used as diagnostic tools for identification of disease processes, 
as a mean to determine disease extension, as an indicator of treatment response and as a 
predictor of disease prognosis (Atkinson et al., 2001). Although cardiac biomarkers have not 
yet been included in the general veterinary biochemical profile, along with renal and hepatic 
biomarkers, they are gaining importance in the clinical work-up in small animal practice 
(Langhorn & Willesen, 2016). Presently, in veterinary medicine, the most reliable biomarkers 
for cardiac diseases are cardiac troponin I (cTnI) and amino-terminal brain natriuretic peptide 
(NT-proBNP) (Baisan, De Rosa, Di Loria, Vulpe, & Piantedosi, 2016). 
Troponin can be found in the cardiac muscle cells – the cardiomyocytes. It mediates the 
interaction between the actin and myosin filaments within the sarcomeres, regulating cardiac 
muscle contraction, through the presence of calcium. Troponin consists of three subunits: 
troponin T, troponin I and troponin C. Cardiac troponin C has a skeletal isoform that is 
completely homologous to it, which is why this subunit cannot be used as a cardiac biomarker. 
Furthermore, troponin T is considered less sensitive than troponin I and is only released in 
more severe cardiac injuries. Hence, troponin I is the most used cardiac troponin in the 
veterinary field (Langhorn & Willesen, 2016). 
Given that troponins are exclusively found intracellularly, their presence in circulation only 
occurs when there is cardiomyocyte destruction and membrane rupture, resulting in a quick 
rise in the serum troponin levels. The continuous breakdown of the contractile apparatus will 
culminate with a sustained increase of troponin concentrations that can last for days, allowing 
its measurement (Baisan et al., 2016; Langhorn & Willesen, 2016).  
This biomarker is a very sensitive tool in the detection of acute myocardial injury, although it is 
not specific for any of the possible underlying causes. After myocardial injury, cardiac 
troponin’s serum concentration increases in 3 to 8 hours and reaches a peak concentration in 
12 to 24 hours. Most of the troponin in the cell is bound to its contractile apparatus, also known 
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as the structural pool, while a smaller portion of troponin is found free in the cytosol, which 
constitutes the cytosolic pool. When cardiomyocyte injury occurs, the cytosolic pool is quickly 
released into circulation, which results in a rapid rise in troponin levels. On the other hand, the 
structural pool is released into circulation as the contractile apparatus is damaged, resulting in 
a much slower release. Troponin levels can then remain elevated for days to weeks following 
the initial injury, which provides a good method for the diagnosis of myocardial damage 
(Langhorn & Willesen, 2016). 
On the other hand, patients with mild cardiac disease often have normal cTnI concentrations 
(Oyama, 2013). In fact, in dogs with MMVD, the use of high sensitivity assays is needed in 
order to detect the low cTnI levels. Nevertheless, it has been shown that circulating cTnI 
concentrations increase with the severity of MMVD. It was hypothesized that this increase was 
caused by a continuous release of cTnI secondary to the ongoing cardiac remodelling, which 
suggests that cTnI analysis may provide a better awareness of the degree of remodelling in 
dogs with MMVD (Ljungvall et al., 2010). Another study showed that high cTnI concentrations 
are associated with lower survival time, indicating that this diagnostic method could potentially 
be used as a prognostic tool in MMVD (Hezzell et al., 2012). 
From another side, natriuretic peptides have recently gained importance as cardiac biomarkers 
(Lima & Ferreira, 2017). In veterinary medicine, the NT-proBNP is the natriuretic peptide most 
commonly used to evaluate the presence of heart disease. BNP is not useful has a biomarker 
because it has a very short half-life (about 90 seconds). On the other hand, NT-proBNP has a 
longer half-life, of approximately 120 minutes, and also seems to be more stable during sample 
collection (Lima & Ferreira, 2017). 
Increased plasma levels of natriuretic peptides are found in patients with heart disease 
(Haggstrom et al., 2000). Indeed, it has been shown that in dogs with signs of respiratory 
distress and cough, NT-proBNP measurements help determine whether those signs are 
caused by a primary pulmonary disease or whether they are due to congestive heart failure 
(Fine, Declue, & Reinero, 2008). These findings suggest that NT-proBNP is a good diagnostic 
tool to consider in dogs with respiratory signs when routine diagnostic tests are unclear 
(Oyama et al., 2013). The consensus statement issued by the ACVIM recommends the use of 
NT-proBNP in all symptomatic dogs, along with other diagnostic tests, in order to determine 
whether or not these signs are caused by heart failure (Keene et al., 2019). 
The usefulness of NT-proBNP measurements in the prediction of heart failure onset in dogs 
with MMVD has been reported. In a former study, 55 dogs with preclinical MMVD were 
monitored for 12 months, after which it was detected that the NT-proBNP concentrations were 
significantly higher in dogs that developed heart failure, while dogs that remained preclinical 
presented lower concentrations (Chetboul et al., 2009). Another study with 39 dogs with mitral 
regurgitation attributed to MMVD stated that dogs with severe mitral regurgitation had higher 
NT-proBNP levels than dogs with less severe mitral regurgitation (Tarnow et al., 2009). Both 
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these studies show that NT-proBNP can be used in the detection of worsening preclinical 
MMVD. In fact, some authors recommend the use of NT-proBNP in asymptomatic dogs with 
MMVD with evidence of cardiac enlargement on echocardiography or radiography, as a means 
to determine the likelihood of development of heart failure (Oyama et al., 2013). 
Specific guidelines regarding the use of cTnI and NT-proBNP in the cardiac workup are still 
not available (Oyama, 2013). It is important to attain that the measurement of these biomarkers 
is not necessary to achieve a diagnosis of MMVD. In comparison, the presence of a left-apical 
systolic heart murmur is a more reliable sign of this disease (Oyama et al., 2013; Baisan et al., 
2016).  
 
4.2– ECHOCARDIOGRAPHY 
Echocardiography is a non-invasive diagnostic ultrasound exam that uses sound waves that 
are sent from a transducer and reflected from soft tissue structures, allowing the visualization 
of the ventricles and atria, the aorta and pulmonary artery, the auricular appendages and all of 
the cardiac valves. Furthermore, this diagnostic method grants an assessment of valvular 
lesions, cardiac chamber dimensions and cardiac function, and an evaluation of blood flow and 
myocardial motion (Boon, 2011). 
There are several known imaging ultrasound modes as will be further explained: 
 
2D echocardiography 
Two-dimensional echocardiography produces an image of the heart that has depth and width, 
resulting in a two-dimensional image. When the sound waves are uninterruptedly fired and 
received from the transducer, they generate multiple two-dimensional images, originating a 
real-time moving image of the heart – also called B-Mode ultrasound (Boon, 2011). This 
provides an observation of all cardiac structures and possible lesions, abnormal cardiac 
chamber dimensions, anomalous cardiac wall motion and presence of pleural and pericardial 
effusions (Fuentes, 2015). In MMVD patients, 2D echocardiography allows the identification of 
valvular lesions, mitral valve prolapse and rupture of the chordae tendineae. Furthermore, 
when mitral regurgitation is significant enough to cause volume overload, we may visualize left 
atrial enlargement and left atrial rupture, an uncommon but possible complication of MMVD 
that can also result in pericardial effusion (Chetboul & Tissier, 2012). 
Different imaging planes or views can be obtained with 2D echocardiography and the names 
of the planes are related to their orientation towards the left side of the heart. Therefore, a 
plane that transects the left ventricle parallel to the long axis of the heart is called a long axis 
plane or view. In contrast, a plane that transects the left ventricle perpendicular to the long axis 
of the heart is known as a short axis view (Thomas et al., 1994). 
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Right parasternal long axis four-chamber view 
The right parasternal long axis four-chamber view is usually the first image to be obtained in 
the echocardiographic examination (Thomas et al., 1994). This view allows good visualization 
of the four heart chambers and both the tricuspid and mitral valve. The four chamber view also 
allows the determination of the left atrium maximal dimension by drawing a line that divides 
the left atrium into two identical halves, parallel to the mitral valve annulus (Figure 1A) (Boon, 
2011). 
 
Right parasternal long axis left ventricular outflow view 
This second view is usually obtained by doing a slight clockwise rotation of the transducer from 
the four-chamber view (Thomas et al., 1994). This will reveal the aorta, aortic valve and left 
ventricular outflow tract, while the left atrium can be seen below the aorta, on the right side of 
the image (Figure 1B). The right atrium and tricuspid valve can also be seen in this view, but 
the four-chamber view allows a better assessment of these structures. This view is usually 
used to determine the aortic root dimension. This dimension is obtained by drawing a line 
delineating the aortic annulus (Boon, 2011). 
 
Figure 1. Right parasternal long axis four-chamber view (A) and left ventricular outflow view 
(B). Courtesy of Elizabeth Bode, University of Liverpool. 
 
 
Right parasternal short axis left ventricle views 
On these views, the right ventricle appears at the top of the image, while the left ventricle 
appears at the bottom, below the interventricular septum (Figure 2A) (Boon, 2011). These 
planes can be obtained by doing a 90º clockwise rotation of the transducer from the long axis 
views. The ventricles should be visualized through different planes, namely at the level of the 
mitral valve, chordae tendineae, papillary muscles and of the left ventricular apex (Thomas et 
al., 1994). 
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Right parasternal short axis view of the heart base 
At the level of the heart base, we can acquire two different planes: the aorta and left atrium 
view (Figure 2B) and the pulmonary artery view (Figure 2C). In the aortic view, the aorta and 
its three cusps are seen as a circle in the middle of the image, creating the “Mercedes sign”. 
This is the most commonly used view to assess the left atrial dimension to the aortic root 
diameter (LA:Ao). To measure this ratio, the frame just after the aortic valve closure is selected, 
and both the aortic and left atrial diameter are measured. With the pulmonary artery view, the 
pulmonary artery can be visualized in its length. (Boon, 2011). 
 
Figure 2. Right parasternal short axis left ventricle view at the level of the papillary muscles 
(A), heart base aorta and left atrium view (B) and heart base pulmonary artery view (C). 
Courtesy of Elizabeth Bode, University of Liverpool. 
 
 
 
 
 
 
 
 
 
 
 
Left parasternal five-chamber and four-chamber views 
On both the five-chamber (Figure 3A) and four-chamber (Figure 3B) views the ventricles are 
seen on top of the image, while the atria appear at the bottom, with the tricuspid and mitral 
valve. On the five-chamber view, the aorta can also be visualized in its length, descending 
between the two atria  (Boon, 2011). 
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Figure 3. Left parasternal five-chamber (A) and four chamber view (B). Courtesy of Elizabeth 
Bode, University of Liverpool. 
 
M-mode echocardiography 
M-mode echocardiography, also known as motion mode, displays the cardiac structures in a 
one-dimensional image. In order to create a M-mode image, we select one of the sound beams 
used to generate a two-dimensional image, so that only the structures struck by that one sound 
beam are seen. The image has the right ventricle at the top, followed by the interventricular 
septum, the left ventricular chamber and the left ventricular free wall at the bottom (Figure 4) 
(Boon, 2011).  
 
Figure 4. Left ventricular M-mode image. Courtesy of Elizabeth Bode, University of Liverpool. 
 
 
 
 
 
 
 
 
 
 
 
 
The resulting image appears as a distance-time graph, in which the vertical axis represents 
depth and time is seen along the horizontal axis. This mode is commonly used for measuring 
chamber dimensions and detecting slight changes in wall and valve motion. M-mode is mostly 
used for accurate assessment of size and function at the level of the left ventricle, mitral valve 
and aortic root (Boon, 2011; Fuentes, 2015). 
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To achieve genuine measurements using M-mode, the cursor must be perpendicular to the 
cardiac structures measured. In M-mode, we can visualize the movement of the interventricular 
septum and the left ventricular free wall through the cardiac cycles; in systole, the 
interventricular septum and the left ventricular free wall move towards each other, while in 
diastole they move away from one another (Madron, 2016b). In dogs, left ventricular M-mode 
can be obtained from the right parasternal long axis left ventricular outflow view (Figure 1B) or 
from the right parasternal short axis view (Figure 2A). In the right parasternal long axis left 
ventricular outflow view, the M-mode cursor is placed perpendicular to the interventricular 
septum and left the ventricular free wall, between the tips of the mitral valve leaflets and the 
left ventricular papillary muscles. Alternatively, when the right parasternal short axis view is 
used, the cursor is positioned over the interventricular septum and the free wall at the level of 
the chordae tendineae, bisecting the left ventricle in two identical halves (Boon, 2011). Both 
these views allow the measurement of two important parameters: the left ventricular internal 
diameter at end diastole (LVIDd) and the left ventricular internal diameter at end systole 
(LVIDs) (Madron, 2016b). 
LVIDd reflects the maximal ventricular filling when the heart is relaxed and is used to determine 
whether there is left ventricular volume overload. On the other hand, LVIDs reflects the heart’s 
systolic function (Boon, 2011). A previous study reported that both LVIDd and LVIDs increase 
in MMVD prior to the development of left-sided heart failure, suggesting progression to 
myocardial failure before the onset of heart failure (Lord et al., 2010). Both these 
measurements are made from the top of the endocardial surface of the interventricular septum 
to the top of the left ventricular free wall.  
Another important parameter that is obtained with M-mode is Fractional Shortening (FS), which 
is a measurement of left ventricular function. FS is calculated with the mathematical formula 
𝐹𝑆 =
𝐿𝑉𝐼𝐷𝑑−𝐿𝑉𝐼𝐷𝑠
𝐿𝑉𝐼𝐷𝑑
 × 100, in which the percentage obtained represents the change in left 
ventricular size between its filling and emptying (Boon, 2011). FS often increases with mitral 
regurgitation due to increased left ventricular emptying during systole. This is related to the 
fact that in MMVD there is lower afterload as part of the left ventricular stroke volume goes to 
the left atrium before the opening of the aortic valve (Madron, 2016a). 
Electrocardiography should be used for measuring purposes, to assure the reliability of the 
results and to guarantee consistency between different operators (Boon, 2011). The American 
Society of Echocardiography (ASE) has issued recommendations for M-mode measurements 
in human patients and the same guidelines are used for veterinary medicine (Sahn, DeMaria, 
Kisslo, & Weyman, 1978; Boon, 2011). The ASE recommends that LVIDd should be measured 
at the beginning of the QRS complex, which corresponds to the maximal ventricular filling after 
atrial contraction. On the other hand, LVIDs should be measured at the nadir of interventricular 
septal motion (Sahn et al., 1978; Madron, 2016b). Different dog breeds can differ a lot in 
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weight, which is why these parameters should take into account body weight (Cornell et al., 
2004). 
 
Doppler echocardiography 
Doppler echocardiography analyses the direction, velocity and timing of blood flow and 
myocardial motion based on the Doppler effect. The Doppler effect is known as the change in 
frequency, in this case of a sound wave, in relation to a target. When both the source of the 
sound wave and the target are stationary, the frequency of the transmitted and reflected sound 
waves is the same. When the target is moving towards the source it reflects an increased 
number of sound waves, so the frequency of the reflected sound waves will be superior to the 
frequency of the transmitted waves. On the contrary, when the target moves away from the 
source, it will reflect fewer sound waves, so that the frequency of the reflected wave will be 
inferior (Boon, 2011). This change in frequency that occurs when a sound wave hits a moving 
target is known as Doppler shift and is proportional to the speed at which the target is moving. 
This helps to determine the velocity of the target, which in echocardiography represents the 
blood cells, if the frequency of the transmitted wave and the reflected wave is known (Fuentes, 
2015; Madron, 2016c). 
Doppler examination studies the characteristics of the intracardiac blood flows and detects the 
presence of abnormal flows. An abnormal direction of blood flow is usually associated with 
valvular insufficiency, while abnormal flow velocities result from abnormal chamber pressure 
(Fuentes, 2015). There are different types of Doppler echocardiography as will be further 
discussed (Madron, 2016c). 
Pulsed wave Doppler examines blood flows at very specific sites (Boon, 2011). In Pulsed wave 
Doppler the sound beams are sent as pulses of waves while the transducer acts as a 
transmitter or a receiver at different times. The main limitation of this Doppler mode is the fact 
that it cannot accurately determine the maximal velocity of the blood flow (Fuentes, 2015). 
Continuous wave Doppler analyses the blood flow all along the sound beam (Boon, 2011). In 
this Doppler mode, the transducer receives and transmits sound waves at the same time. This 
allows the detection of higher velocity values (Fuentes, 2015). However, Continuous wave 
Doppler cannot localize the exact origin of the blood flow (Madron, 2016c). 
Colour flow Doppler is a form of Pulsed wave Doppler in which the blood flow is visible in colour 
on 2D images. It uses a colour code for different flow velocities and directions; when the flow 
moves towards the transducer it appears in red, while if the flow moves away from the 
transducer it appears in blue. Colour flow Doppler can detect the presence of turbulent flow, 
which can be secondary to valvular insufficiency, in which the flow is displayed as a mosaic of 
colours that ranges between the red and blue spectrum (Boon, 2011; Madron, 2016c). Semi-
quantification of the degree of mitral regurgitation is also possible with Colour flow Doppler, 
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which provides a quick assessment of the severity of mitral regurgitation (Chetboul & Tissier, 
2012). 
Finally, tissue Doppler imaging (TDI) records the velocity of myocardial motion and is applied 
to assess myocardial synchronicity and systolic and diastolic function (Boon, 2011). TDI is 
mostly used to detect diastolic dysfunction, therefore its relevance in MMVD cases is limited 
(Fuentes, 2015). 
The ACVIM consensus guidelines recommends echocardiographic examination for all stage 
B and stage C patients. Echocardiography identifies the presence of MMVD and quantifies the 
degree of chamber remodelling and cardiac function. Furthermore, it identifies the presence of 
increased left atrial pressures and pulmonary hypertension, which can ultimately result in left-
sided heart failure. Echocardiography also aids in the recognition of stage B2 dogs, in which 
the degree of cardiac remodelling is enough to start medical therapy. Patients with a LA:Ao 
ratio ≥ 1.6 in the right parasternal short axis view in early diastole and with a LVIDd ≥ 1.7 
measured with M-mode echocardiography meet the stage B2 criteria (Keene et al., 2019). 
 
4.3– RADIOGRAPHY 
Thoracic radiographs are an essential tool for monitoring patients with MMVD (Borgarelli & 
Haggstrom, 2010). The ACVIM consensus statement recommends the use of thoracic 
radiography in all dogs with MMVD in order to assess the hemodynamic significance of the 
disease. In stage B patients, thoracic radiographs are also important to acquire a baseline 
radiograph of the asymptomatic patient, as this will allow close monitoring of disease 
progression. Care should be taken when assessing thoracic radiographs, so that other 
possible concomitant primary respiratory diseases can be excluded, which could contribute to 
the clinical signs, such as the cough (Keene et al., 2019). 
Thoracic radiographs allow an assessment of the severity of mitral regurgitation by 
visualization of left atrial enlargement, general heart enlargement and signs of left-sided 
congestive heart failure (Lord & Suter, 1999). Left atrial enlargement is the earliest radiographic 
sign and is considered more reliable for indirect estimation of mitral regurgitation than general 
heart enlargement (Lord & Suter, 1999; Hansson, Haggstrom, Kvart, & Lord, 2009). Left atrial 
enlargement is usually associated with dorsal displacement of the trachea and left mainstem 
bronchus on the lateral view, a dorsocaudal bulging of soft tissue opacity on the lateral view 
and an area of increased opacity superimposed to the cardiac silhouette on the ventrodorsal 
view (Hansson et al., 2009). Dogs with MMVD normally do not develop signs of heart failure 
without some degree of left atrial enlargement, except on those rare cases when a rupture of 
a first-order chordae tendineae leads to acute heart failure. Therefore, assessment of left atrial 
size, either by radiography or echocardiography, is very important to identify patients at risk of 
developing heart failure (Malcom, Visser, Phillips, & Johnson, 2018). 
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A recent study described an alternative method to estimate left atrial size radiographically, 
known as vertebral left atrial size (VLAS). To determine the VLAS, a line is drawn on the lateral 
view, starting from the centre of the most ventral aspect of the carina and finishing in the most 
caudal aspect of the left atrium where it intersects with the dorsal border of the caudal vena 
cava. Afterwards, a second line with the same length as the first is drawn, beginning on the 
cranial edge of the 4th thoracic vertebra. A VLAS cut-off value of 2.3 has been suggested as 
an indicator of left atrial enlargement. Results suggest that this new method is a good predictor 
of left atrial enlargement in dogs with MMVD and that it has a good correlation with the 
echocardiographic measurements of the left atrium (Malcom et al., 2018). 
General heart enlargement can be judged by a subjective increase of the cardiac silhouette’s 
length and width, by a dorsal displacement of the trachea on the lateral view, by observation 
of a rounder cardiac silhouette and by the measurement of the Vertebral Heart Score (VHS) 
(Hansson et al., 2009). The VHS allows an objective evaluation of the dimensions of the 
cardiac silhouette, by measuring the cardiac long axis and short axis on the lateral view. These 
two axes are then summed up and compared with the length of the thoracic spine, starting on 
the cranial border of the 4th thoracic vertebra (Guglielmini et al., 2009). A VHS value of 10.5 
has been suggested as the upper limit to a normal heart size, but since some dog breeds are 
known to have variations in thoracic conformation and cardiac dimensions, normal VHS values 
have been proposed for other breeds (Lamb, Wikeley, Boswood, & Pfeiffer, 2001; Buchanan, 
2015). This is considered a good method to evaluate cardiomegaly associated with eccentric 
hypertrophy secondary to volume overload, which is the case of MMVD (Nakayama, 
Nakayama, & Hamlin, 2001; Guglielmini et al., 2009). Nevertheless, this technique should be 
used in combination with other radiographic signs (Guglielmini et al., 2009). The inclusion 
criteria to decide whether or not a stage B dog should start medical treatment with pimobendan 
has been established (Boswood et al., 2016). Because these criteria rely on echocardiography, 
and since this diagnostic method may not be available for all veterinary clinical practices, it has 
been proposed that patients with subclinical MMVD and a VHS > 11.7 would benefit from 
starting therapy with pimobendan (Vitt et al., 2017). 
The determination of the presence of left-sided heart failure is based on the observation of 
radiographic signs of pulmonary oedema, which include the dilation of the pulmonary veins 
and an increased opacity of the pulmonary field. (Hansson et al., 2009). The elevation of left-
sided filling pressures in the left atrium can cause pulmonary venous hypertension, which will, 
in turn, increase the width and opacity of the pulmonary veins. These veins become then more 
evident than the corresponding pulmonary arteries (Ware & Bonagura, 1999; Rosenkranz et 
al., 2016). Pulmonary venous hypertension is not necessarily a sign of heart failure, but it does 
precede the onset of heart failure, hence, it can be used to identify at-risk patients (Bahr, 2018).  
Radiographically, the increased lung opacity can be observed as an interstitial pattern, an 
alveolar pattern or a mixed interstitial-alveolar pattern (Diana et al., 2009; Hansson et al., 
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2009). When heart failure develops secondary to a volume overload caused by mitral 
insufficiency, the pulmonary capillary pressure is increased. This will lead to a movement of 
fluid to the interstitial space and when this movement exceeds the capacity of the lymphatic 
drainage, there is an accumulation of interstitial fluid (Ware & Bonagura, 1999). Hence, an 
interstitial pattern is expected in the earlier phase of cardiogenic pulmonary oedema (Diana et 
al., 2009). As the capillary fluid continues to accumulate, the interstitial pressure rises and the 
fluid begins to build up in the alveoli, which is why the alveolar pattern appears in a later phase 
of heart failure (Ware & Bonagura, 1999; Diana et al., 2009). 
In dogs, it is believed that cardiogenic pulmonary oedema develops initially in the perihilar 
region (Ware & Bonagura, 1999). However, a previous study with 61 dogs with pulmonary 
oedema secondary to mitral insufficiency reported that only 11.5 % of these dogs presented 
with a perihilar distribution of the oedema, while the remaining dogs had either a diffuse (18%) 
or a patchy (70.5%) distribution. These findings suggest that at the time the diagnosis is made, 
pulmonary oedema has spread to other areas of the lung field, making other distributions more 
prevalent (Diana et al., 2009). The same study stated that 65.6% of the dogs had a symmetric 
radiographic distribution of the pulmonary oedema, affecting mainly the caudal lung lobes. 
From the remaining 21 dogs with an asymmetric distribution, 18 had involvement of the right 
caudal lung lobe. The authors suggested that the asymmetry seen in these dogs could be 
related to a central or an eccentric mitral regurgitant jet. Nevertheless, more studies are 
necessary to confirm this hypothesis (Diana et al., 2009). 
Pulmonary arterial hypertension is also a common complication in dogs with MMVD (Borgarelli 
et al., 2015). Initially, pulmonary arterial hypertension develops secondary to the increased 
left-sided filling pressures and pulmonary venous hypertension. As these pressures continue 
to increase, the pulmonary capillaries begin to remodel. This will increase the vascular 
resistance to the blood flow, further increasing the pulmonary arterial pressure. At this stage, 
the remodelling changes in the arterial bed can be permanent, and the pulmonary arterial 
pressure cannot be reversed (Guazzi & Arena, 2010). On radiography, this can be seen as an 
enlargement of both the pulmonary arteries and veins, although this is an uncommon finding 
(Bahr, 2018). Increased pulmonary arterial pressures can, in turn, induce right ventricular 
remodelling and culminate with right-sided heart failure (Guazzi & Arena, 2010). Usually, in 
these cases, we can identify radiographic signs of right heart enlargement, 
hepatosplenomegaly, and presence of pleural or abdominal fluid (Bahr, 2018). 
 
4.4– ELECTROCARDIOGRAPHY 
Electrocardiography is another important diagnostic tool that allows an assessment of heart 
rate and heart rhythm (Wess & Torti, 2018). Arrhythmias are a rather common finding in dogs 
with MMVD, although these are rarely symptomatic. In a previous study in which 36 dogs with 
MMVD underwent a Holter monitoring, 50% of the dogs with subclinical disease had 
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supraventricular arrhythmias, while 57% had ventricular arrhythmias and 21% had both 
ventricular and supraventricular arrhythmias. Among the population of dogs with clinical 
disease, 72% had supraventricular arrhythmias, 86% had ventricular arrhythmias and 68% had 
both ventricular and supraventricular arrhythmias. Hence, both the frequency and the severity 
of the arrhythmias seems to be higher in patients with clinical disease. (Crosara et al., 2010). 
In this context, atrial fibrillation is a common supraventricular arrhythmia seen in dogs with 
MMVD. The development of atrial fibrillation is associated with severe atrial dilation, which in 
MMVD is secondary to chronic volume overload (Crosara et al., 2010; Wess & Torti, 2018). 
This is especially important because atrial fibrillation has been associated with a higher rate of 
mortality in medium and large breed dogs with MMVD (Jung, Sun, Griffiths, & Kittleson, 2016). 
Electrocardiography can also help to determine whether a patient’s clinical signs can be 
attributable to heart failure. Dogs with cough and dyspnoea that present with sinus arrhythmia 
and reasonably slow heart rates are less likely to be in heart failure. On the other hand, dogs 
with the same clinical signs and with sinus rhythm or sinus tachycardia are much more likely 
to be in heart failure (Keene et al., 2019). 
 
4.5– FURTHER DIAGNOSTIC RECOMMENDATIONS 
The ACVIM consensus guidelines provides further recommendations for the diagnosis and 
monitoring of dogs with MMVD. Stage A dogs, which are the breeds with a known 
predisposition to MMVD, namely CKCS, Dachshunds and miniature and toy Poodles, should 
be submitted to regular check-ups in order to assess if the disease has progressed. 
Furthermore, all stage B patients, which are the ones that are already affected with the disease 
but have not yet developed heart failure, should also have their blood pressure measured, in 
order to exclude concurrent systemic hypertension (Keene et al., 2019). 
For stage C and D patients, which are the ones with present or past clinical signs of heart 
failure, refractory or not to treatment, basic laboratory tests and blood pressure measurements 
are also recommended, alongside with echocardiography, serum NT-proBNP measurement 
and thoracic radiography. These laboratory tests include a complete blood count, a serum 
biochemical profile and urinalysis. This is especially important if the clinician is planning to start 
treating the heart failure (Keene et al., 2019). 
 
5. TREATMENT 
Treatment of dogs with MMVD should be done according to the clinical stage of the disease. 
The ACVIM consensus statement provides treatment guidelines according to clinical staging 
(Keene et al., 2019). 
Dogs that meet the stage B2 criteria should start treatment with pimobendan (Keene et al., 
2019). Pimobendan inhibits phosphodiesterase III activity and increases calcium sensitivity, 
24 
which increase myocardial contractility and promote arteriolar vasodilation, reducing afterload 
and improving cardiac output (Atkins & Haggstrom, 2012). Pimobendan prolongs the onset of 
heart failure in dogs with MMVD by approximately 15 months and reduces the likelihood of 
development of heart failure by nearly one-third (Boswood et al., 2016). 
The ACVIM panel also recommends starting dietary treatment in stage B2 patients. This diet 
should contain mild sodium restriction and should be highly palatable with adequate protein 
and caloric content in order to maintain a good body condition (Keene et al., 2019).  
Half of the ACVIM panellists also advise starting medical treatment with angiotensin-converting 
enzyme inhibitors (ACEI) (Keene et al., 2019). ACEI such as enalapril, benazepril and 
captopril, block the angiotensin converting enzyme that is responsible for the conversion of 
angiotensin I to angiotensin II, suppressing the effects of the RAAS. It is believed that RAAS 
suppression will contribute to a more stable haemodynamic condition, by inhibiting the 
vasoconstriction of arterioles and veins, reducing fluid retention and preventing cardiac 
remodelling (Atkins & Haggstrom, 2012). A former study reported that chronic treatment of 
asymptomatic MMVD patients with enalapril delayed the onset of heart failure by 
approximately 4 months, which shows that this drug is not as effective as pimobendan in pre-
clinical patients (Atkins et al., 2007).  
For stage C patients in need of acute treatment in a hospital basis, intravascular (IV) 
furosemide should be started (Keene et al., 2019). Furosemide is a diuretic that acts on the 
ascending portion of the loop of Henle. By promoting diuresis, furosemide decreases 
intravascular volume, reduces left ventricular filling pressures and allows lymphatic drainage 
of tissue fluid, contributing to the resolution of pulmonary oedema (Strickland, 2015). In 
patients with life-threatening pulmonary oedema, administration of furosemide at a constant 
rate infusion (CRI) should be considered. Once the patient’s pulmonary oedema and 
respiratory signs improve, IV furosemide should be discontinued and per os (PO) furosemide 
should be started. It is important that patients receiving diuretic therapy have free access to 
water (Keene et al., 2019).  
Acute stage C patients may also need oxygen supplementation and thoracentesis or 
abdominal paracentesis in order to remove effusions that contribute to respiratory distress. 
Some dogs may also require the use of sedation. The ACVIM panellists frequently resort to 
opioids, such as butorphanol, or a combination of an opioid with an anxiolytic agent, like the 
combination of buprenorphine with acepromazine (Keene et al., 2019). Opioids do not affect 
myocardial contractility or vascular tone, which is why they are often used in cardiac patients 
(Strickland, 2015). 
As previously mentioned, chronic stage C patients should be continued with PO furosemide. 
Patients should have their serum creatinine, blood urea nitrogen and electrolyte concentrations 
measured 3 to 14 days after starting their treatment since furosemide can lead to the 
development of azotaemia and hypokalaemia (Strickland, 2015; Keene et al., 2019). If medical 
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treatment with pimobendan or ACEI (such as enalapril or benazepril) have not yet been 
initiated, then it should be started at this point (Keene et al., 2019).  
Spironolactone is also recommended for medical management of chronic stage C dogs (Keene 
et al., 2019). It has been shown that spironolactone combined with conventional therapy 
reduces the risk of mortality in dogs with MMVD. Spironolactone is an aldosterone receptor-
antagonist that antagonizes the effects of aldosterone in heart failure, by decreasing water and 
sodium retention that contributes to pulmonary oedema and by counteracting cardiac 
remodelling (Bernay et al., 2010). 
For patients that are presented with atrial fibrillation secondary to left atrial enlargement, 
treatment with diltiazem, often in combination with digoxin, is recommended (Crosara et al., 
2010; Keene et al., 2019).  
Dietary treatment in stage C and D patients is also very important, in order to prevent cardiac 
cachexia, which defines muscle loss secondary to chronic heart failure. Cardiac cachexia is 
associated with increased morbidity and mortality and reduced quality of life (Freeman, 2009; 
Keene et al., 2019). In order to prevent cardiac cachexia, an adequate calorie and protein 
intake should be maintained, and a moderate sodium restriction should be ensured. In dogs 
with decreased appetite and muscle loss supplementation with omega-3 fatty acids should 
also be considered (Keene et al., 2019). 
Stage D patients have clinical signs of heart failure unresponsive to conventional treatment, 
hence, these dogs require increasing doses of furosemide or the equivalent dosage of 
torsemide (Keene et al., 2019). Torsemide is also a loop diuretic that has a longer duration of 
action and a greater potency than furosemide. Furthermore, torsemide improves diuresis in 
dogs that have developed diuretic resistance with long-term furosemide treatments (Peddle et 
al., 2012). Torsemide should then be reserved for patients that have developed an inadequate 
response to furosemide (Keene et al., 2019).  
Arterial vasodilators, such as hydralazine or amlodipine, are also recommended in patients 
that can tolerate these (Keene et al., 2019). Arterial vasodilators increase cardiac output and 
decrease mitral regurgitation, by decreasing afterload and allowing a bigger blood volume to 
flow into the aorta (Strickland, 2015). The use of arterial vasodilators should be monitored with 
arterial blood pressure measurement. If the patient develops pulmonary hypertension, the use 
of sildenafil, a phosphodiesterase-5 inhibitor that promotes pulmonary arterial vasodilation, 
should also be considered (Brown, Davison, & Sleeper, 2010; Keene et al., 2019). 
Despite medical advances in the management of heart failure patients, dogs with severe mitral 
regurgitation secondary to MMVD still have a poor prognosis (Serres et al., 2007). Surgical 
treatment for MMVD has successfully improved the survival of dogs with severe mitral 
regurgitation. Nonetheless, mitral valve repair or replacement has been done in only a few 
cases, mostly due to the difficulties in performing cardiopulmonary bypass in veterinary 
patients (Uechi, 2012). 
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6. PROGNOSIS 
Although mitral valve disease is an important cause of left-sided heart failure in dogs, it is 
usually a well-compensated disease with a long preclinical period (Serfass et al., 2006; 
Borgarelli & Haggstrom, 2010).  In one recent study, that included asymptomatic dogs 
diagnosed with MMVD, 82% of the dogs remained asymptomatic 12 months after their 
inclusion in the study (Chetboul et al., 2009). Another study that evaluated the efficacy of 
pimobendan, a selective inhibitor of phosphodiesterase 3, in delaying the onset heart failure in 
dogs with cardiac enlargement secondary to mitral valve disease, showed a median time 
before the onset of heart failure of 1228 days for the pimobendan group and 766 days for the 
placebo group (Boswood et al., 2016). Both these studies provide some evidence that 
preclinical MMVD is a relatively benign condition in dogs. Nevertheless, it is important to retain 
that MMVD remains an important cause of heart failure and cardiac-related death (Borgarelli 
et al., 2012). 
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III INTRODUCTION AND OBJECTIVES 
 
MMVD is considered the most common cardiovascular disease reported in dogs and a high 
prevalence has been reported in dogs attending primary-care practices in England (Sisson et 
al., 1999; Mattin et al., 2015). MMVD can result in mitral regurgitation, causing an increased 
volume load which often culminates with left-sided heart failure (Strickland, 2015). However, 
most patients undergo a long preclinical period before experiencing any clinical signs 
(Boswood et al., 2016). 
Although many risk factors have been identified (Mattin et al., 2015), little has yet been 
published regarding the possible effects that neutering status could have on the development 
of MMVD. Hence, the purpose of this retrospective study was to assess whether neutering 
status affects cardiac remodelling in both female and male patients from a study population of 
582 dogs diagnosed with MMVD. 
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IV MATERIALS AND METHODS 
 
1. INCLUSION CRITERIA  
For this retrospective study, the database of the Small Animal Teaching Hospital, University of 
Liverpool, United Kingdom, was searched for all the dogs diagnosed with MMVD between 
January 2008 and December 2016.  
Dogs were excluded if BW (body weight) > 20 kg or if they also suffered from significant 
congenital heart disease, such as mitral valve dysplasia, or an acquired cardiovascular 
disorder that could affect our measurements, such as dilated cardiomyopathy. Dogs with 
clinical findings that could affect cardiac remodelling, such as systemic hypertension, anaemia 
or hypovolaemia, were also excluded. Finally, dogs were excluded if, at the time of the heart 
scan they presented with pyrexia of unknown origin, which could be caused by bacterial 
endocarditis. 
Dogs with mild congenital heart disease were included if this was considered to be 
haemodynamically insignificant, for example, mild aortic stenosis, mild pulmonic stenosis, 
minor atrial septal defect or a restrictive ventricular septal defect. 
The study protocol was reviewed and approved by the Veterinary Research Ethics Committee 
of the University of Liverpool (ethical approval number: VREC483). 
 
2. CLINICAL DATA 
The hospital’s patient record and management software (Tristan) was consulted and all dogs 
with a diagnosis of MMVD were recruited. Afterwards, the same software was used to review 
the medical records and to determine the date of birth, sex, neutering status and breed of the 
previously identified patients. An assessment of the dog’s clinical history was also made in 
order to identify any concomitant systemic diseases that could potentially influence the results. 
The hospital’s echocardiographic database (EchoPAC) was consulted, and the 
echocardiographic measurements of the previously identified patients were recorded. 
To help assess the association between neutering status and cardiac remodelling, dogs were 
categorized in four groups: FE (female entire), FN (female neutered), ME (male entire) and 
MN (male neutered). 
 
3. ECHOCARDIOGRAPHIC DATA 
Transthoracic two-dimensional (2D) echocardiographic studies were performed by board-
certified (ECVIM or ACVIM) cardiologists or cardiology residents under their supervision. A 
single-lead electrocardiogram was acquired simultaneously. The standard echocardiographic 
views were obtained with the dogs in right and left lateral recumbency; the images were 
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recorded and then assessed for offline measurements. None of the dogs were sedated during 
the echocardiographic examination. 
For each dog the LA:Ao ratio was assessed from the right parasternal short-axis view with the 
2D method (Figure 5). This ratio was measured after the QRS complex, at the first frame in 
which the aortic valve closes, which indicates the beginning of diastole. The measurements 
were considered within normal limits if LA:Ao < 1.5 (Hansson et al., 2002). 
 
Figure 5. Representation of a right parasternal short-axis view used for measuring the LA:Ao 
ratio. Courtesy of Elizabeth Bode, University of Liverpool. 
 
 
 
 
 
 
 
 
 
 
 
 
The LAmax:Ao ratio was obtained from the 2D Mode by dividing the left atrium maximal 
dimension measured in the right parasternal long axis four-chamber view (Figure 6) with the 
maximal distance between the aortic leaflets obtained in the right parasternal long-axis left 
ventricular outflow view (Figure 1B), as previously reported. The maximum dimension of the 
left atrium (LA) was obtained during systole, at the last frame before the mitral valve opened, 
by splitting the LA into two halves parallel to the mitral valve annulus. LAmax:Ao > 2.4 was 
considered a sign of cardiac remodelling (Strohm, Visser, Chapel, Drost, & Bonagura, 2018). 
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Figure 6. Representation of a right parasternal long-axis four chamber view used for 
measuring the LAmax:Ao ratio. Courtesy of Elizabeth Bode, University of Liverpool. 
 
 
 
 
 
 
 
 
 
 
 
 
The left ventricular internal diameter at end diastole (LVIDd) and the left ventricular internal 
diameter at end systole (LVIDs) were measured using M-mode and obtained from the right 
parasternal short axis view at the level of the chordae tendineae (Figure 7). These 
measurements were indexed for body weight as previously described. A LVIDd > 1.85 and a 
LVIDs > 1.26 were considered abnormal (Cornell et al., 2004). 
 
Figure 7. Representation of a M-mode image obtained from the right parasternal short axis 
view at the level of the chordae tendineae used for measuring the LVIDd and the LVIDs. 
Courtesy of Elizabeth Bode, University of Liverpool. 
 
 
 
 
 
 
 
 
 
 
 
The number of echocardiographic exams for each case was noted, but only the measurements 
of the last examination were included in the present study. 
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4. STATISTICAL ANALYSIS 
Data was collected and inserted into Excel (Microsoft, USA). Statistical analysis was performed 
using SPSS version 24.0 (IBM, USA). The normality of the data was assessed by visual 
inspection of histograms and with the Kolmogorov-Smirnov normality test. 
Descriptive statistics were applied. Results were reported as mean (± standard deviation) 
when they were normally distributed and as median (interquartile range) when they were non-
normally distributed. 
Age and BW were compared between the four groups using one-way ANOVA and Tukey HSD 
test. 
The odds ratio was calculated to evaluate the association between the male gender and the 
presence of cardiac remodelling and to evaluate the association between the breed Cavalier 
King Charles spaniel and the presence of cardiac remodelling. 
LVIDs and LVIDd were compared between FE vs FN and ME vs MN using the independent t-
test for normally distributed variables, while LA:Ao and LAmax:Ao were compared using the 
Mann-Whitney U Test for non-normally distributed variables. 
Statistical significance was accepted if p < 0.05.  
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V RESULTS 
 
1. STUDY POPULATION 
Five hundred and eighty-two (n = 582) dogs met the inclusion criteria. Two hundred and fifty-
nine were female (44.5%) [24 FE (4.1%) and 235 FN (40.4%)]. Three hundred and twenty-
three were male (55.5%) [115 were ME (19.8%) and 208 MN (35.7%)]. 
Cavalier King Charles spaniels were the most common breed (n = 176, 30.4%), followed by 
cross breeds (n = 85, 14.68%), English cocker spaniels (n = 57, 9.8%) and Jack Russel terriers 
(n = 25, 4.32%). Other breeds represented included Shih Tzu dogs (n = 21), miniature 
Schnauzer (n = 20),  Yorkshire terrier (n = 19),  West Highland white terrier (n = 16), chihuahua 
(n = 14), bichon frisé (n = 14), English springer spaniel (n = 8), and Staffordshire bull terriers 
(n = 7), among others (table 1). 
There were significant differences in age between FE vs FN (p = 0.010) and FE vs MN (p = 
0.035). Mean age was 8.26 ± 2.96 years for the FE group, 9.41 ± 2.88 years for the FN group. 
Mean age for the ME group was 8.76 ± 3.83 years and 9.22 ± 2.94 years for the MN group. 
There were no significant differences between FE vs ME (p = 0.101), FN vs ME (p = 0.527), 
FN vs MN (p = 0.810) and ME vs MN (p = 0.932).  
BW distribution between ME and MN was significantly different (p = 0.011). The mean BW was 
9.93 ± 3.58 kg for the ME group and 11.97 ± 3.68 kg for the MN group. There were no 
significant differences in BW between FE vs FN (p = 0.960), FE vs ME (p = 0.996), FE vs MN 
(p = 0.474), FN vs ME (p = 0.514) and FN vs MN (p = 0.140). Mean BW for the FE group was 
11.6 ± 2.69 kg and for the FN group was 11.9 ± 4.25 kg. 
 
2. ECHOCARDIOGRAPHIC FINDINGS 
The LVIDd distribution between ME and MN was significantly different (p = 0.045). The mean 
LVIDd was 1.73 ± 0.40 for ME dogs and 1.64 ± 0.38 for MN dogs. There wasn’t a significant 
difference between the FE group and FN group (p = 0.220). The mean LVIDd for FE dogs was 
1.57 ± 0.29 and the mean for the FN group was 1.66 ± 0.35. 
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Graphic 1. Box-and-whiskers plots of LVIDd between Male Entire (ME) vs Male Neutered 
(MN) and Female Entire (FE) vs Female Neutered (FN). 
+ if P<0.05; ++ if P<0.01. 
 
Regarding the LVIDs, between the FE and FN (p = 0.700) and the ME and MN (p = 0.070), 
there were no significant differences between the groups. The mean LVIDs was 0.95 ± 0.18 
for the FE group, 0.96 ± 0.21 for the FN group, 0.97 ± 0.23 for the ME group, and 1.02 ± 0.28 
for the MN group. 
 
Graphic 2. Box-and-whiskers plots of LVIDs between Male Entire (ME) vs Male Neutered (MN) 
and Female Entire (FE) vs Female Neutered (FN). 
 
The LA:Ao distribution between ME and MN was significantly different (p = 0.031). The median 
LA:Ao was 1.45 (1.29 – 1.77) for ME dogs, while for MN dogs the median was 1.43 (1.24 –
1.76). There were no statistically significant differences between the FE and the FN group (p 
= 0.344). The median for the FE group was 1.38 (1.26 – 1.58) and for the FN group was 1.45 
(1.29 – 1.77). 
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Graphic 3. Box-and-whiskers plots of LA:Ao between Male Entire (ME) vs Male Neutered (MN) 
and Female Entire (FE) vs Female Neutered (FN). 
+ if P<0.05; ++ if P<0.01. 
 
LAmax:Ao distribution was significantly different between ME and MN dogs (p = 0.002). The 
median LAmax:Ao was 2.50 (2.15 – 2.98) for the ME group and 2.44 (2.08 – 3.03) for the MN 
group. There were no statistically significant differences between the FE and the FN group (p 
= 0.208). The median for the FE dogs was 2.30 (2.05 – 2.69) and for the FN dogs was 2.50 
(2.15 – 2.98). 
  
Graphic 4. Box-and-whiskers plots of LAmax:Ao between Male Entire (ME) vs Male Neutered 
(MN) and Female Entire (FE) vs Female Neutered (FN). 
+ if P<0.05; ++ if P<0.01. 
 
The male gender was not significantly associated with the presence of cardiac remodelling 
(Odds Ratio 0.97; 95% confidence interval, 0.692 to 1.360). Furthermore, the breed CKCS 
was not significantly associated with the presence of cardiac remodelling (Odds Ratio 1.4; 95% 
confidence interval, 0.979 to 2.068).  
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VI DISCUSSION 
 
This study shows that neutering status may influence the development of MMVD in male dogs.  
Between ME and MN dogs, statistically significant differences were found in LVIDd, LA:Ao and 
LAmax:Ao, even though LVIDs was not significantly different. Given that mean LVIDd and 
median LA:Ao and LAmax:Ao were higher in ME dogs than in MN dogs, this indicates that 
entire male dogs may have a higher risk of developing cardiac remodelling secondary to 
MMVD than castrated dogs. Nonetheless, the echocardiographic changes found between 
male entire and male neutered dogs were rather small, hence it is hard to know whether these 
changes are clinically relevant. On the other hand, between the FE and FN groups no 
statistically significant differences were found. However, since the FE population was rather 
small (n = 24), this sample may not be truly representative of the FE population. Thus, it is 
hard to know whether in fact neutering status affects cardiac remodelling secondary to MMVD 
in the female population. 
Increased LVIDd is associated with worsening left ventricular volume overload, which in MMVD 
is due to haemodynamically significant mitral regurgitation (Boon, 2011). Therefore, LVIDd can 
be used as an indicator of disease severity in MMVD. In a previous study, increased LVIDd 
values were associated with a higher risk of death in patients with MMVD, demonstrating that 
LVIDd could also be used as a predictor of mortality. It was hypothesized that increasing 
ventricular diameters would increase afterload, which would, in turn, increase myocardial work 
and promote decompensation (Moonarmart et al., 2010). 
LVIDs reflects left ventricular systolic function (Boon, 2011). Patients with MMVD and 
moderate heart failure seem to have some degree of systolic dysfunction (Borgarelli et al., 
2007). Reduced myocardial function in MMVD can occur due to lack of adequate eccentric 
hypertrophy when the volume overload stimulates chamber dilation to compensate for the 
mitral regurgitation. Nevertheless, myocardial dysfunction is considered an uncommon finding 
in small breed dogs with MMVD (Borgarelli et al., 2007). LVIDs is not affected by cardiac 
remodelling, since in dilated hearts the myocardium should still be able to shorten to normal 
systolic dimensions. It is only when the intrinsic contractility of the myocardium starts to 
decrease that the left ventricular systolic dimensions will increase (Boon, 2011). Considering 
that high values of LVIDs are not always present in dogs with moderate MMVD and that this is 
not a parameter of cardiac remodelling, this could explain why no significant differences were 
found between ME and MN dogs. 
Left atrial enlargement is related to the severity of mitral regurgitation. Because the left atrium 
has a three-dimensional asymmetrical enlargement, on 2D echocardiography this enlargement 
may not be apparent. Therefore, more than one plane should be used to assess if left atrial 
enlargement is present (King, Gopal, Keller, Sapin, & Schroder, 1994; Boon, 2011). Left atrial 
enlargement secondary to mitral regurgitation is usually seen before there’s any ventricular 
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remodelling (Boon, 2011). The likelihood of developing heart failure increases with increasing 
left atrial dimensions because left atrial enlargement reflects increasing left atrial pressures 
(Rishniw & Erb, 2000). The LA:Ao and LAmax:Ao can be used to assess left atrial enlargement. 
LA:Ao is considered an important prognostic variable and increasing values of LA:Ao has been 
associated with decreased survival (Sargent et al., 2015). The fact that both echocardiographic 
measurements of left atrial enlargement had statistically significant differences between ME 
and MN dogs strongly supports the hypothesis that entire males are more severely affected 
than male neutered dogs. 
Many aspects of the pathophysiology of MMVD remain unclear. Bearing in mind the results of 
this study, it is possible that androgenic hormones could play a role in the pathogenesis of this 
disease. In fact, a previous study reported that testosterone can increase platelet thromboxane 
A2 receptor density in human patients and promote platelet aggregation (Ajayi, Mathur, & 
Halushka, 1995). In rats, it has also been shown that testosterone has the same effect in 
thromboxane A2 receptor density (Matsuda, Ruff, Morinelli, Mathur, & Halushka, 2017). 
Furthermore, in human patients, exogenous testosterone therapy has been associated with 
thrombotic events (Ruige, Ouwens, & Kaufman, 2013). It can then be hypothesized that by 
increasing thromboxane A2 receptor density in the platelets, testosterone may potentiate 
platelet aggregation in the damaged endothelium at the level of the mitral valve, and these 
platelets would, in turn, release a serotonin signal, leading to the activation of the quiescent 
VICs and promoting the extracellular matrix changes that characterize MMVD.  Consequently, 
male entire dogs would develop more severe mitral regurgitation, leading to increasing left 
atrial size and left ventricular internal diameters at end diastole. This theory could then explain 
why male entire dogs with MMVD would be more affected and present more cardiac 
remodelling than neutered dogs. However, it is important to attain in both these studies platelet 
aggregation responses occurred secondary to supraphysiological testosterone concentrations 
(Ajayi, Mathur, & Halushka, 1995; Matsuda et al., 2017); hence, caution is needed when 
extrapolating these results. Nevertheless, it could be worth investigating whether testosterone 
does, in fact, play a role in the pathogenesis of MMVD. 
Male dogs did not present higher odds of developing cardiac remodelling. However, since both 
neutered and entire dogs were considered in this statistical analysis, this finding does not 
necessarily contradict the hypothesis that testosterone may be involved in the pathophysiology 
of MMVD. 
To the author’s knowledge, this is the first study to describe a possible relation between 
neutering status and cardiac changes secondary to MMVD. A former retrospective study that 
examined the prevalence of MMVD and heart failure in 942 small size dog breeds reported 
that the prevalence of MMVD was not significantly changed with neutering status in both 
female and male dogs (Serfass et al., 2006). However, from the 503 male dogs that were 
included in the previous study, only 74 were neutered, while the present study included a much 
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higher number of neutered males (n = 208). Furthermore, in the former study, from the 136 
dogs that had a left-apical systolic murmur, only 63 were subjected to an echocardiographic 
exam and disease severity was not assessed according to the neutering status. 
Dogs with moderate to severe cardiovascular diseases or systemic diseases that could 
potentially affect the echocardiographic measurements were excluded from this study. The 
restriction of enrolment to dogs with body weight inferior to 20 kg allowed the exclusion of dogs 
that could have concurrent dilated cardiomyopathy. Canine dilated cardiomyopathy is 
characterized by cardiac enlargement, normally affecting large and medium-size breed dogs. 
This disease is associated with impaired systolic function, which echocardiographically would 
result in increased LVIDs values, which could affect this study’s results (Stern & Meurs, 2017). 
Cavalier King Charles spaniels were over-represented in this study, accounting for 
approximately one-third of the study population. This data is also in agreement with previous 
studies, in which Cavalier King Charles spaniels were the most prevalent breed among dogs 
with MMVD (Mattin et al., 2015; Mattin, Boswood, Church, & Brodbelt, 2019). Other studies 
also identified Jack Russel terriers, Shih Tzu dogs, Miniature Schnauzer, Yorkshire terriers, 
and chihuahuas as being more predisposed to MMVD (Serfass et al., 2006; Mattin et al., 2019, 
2015). Nevertheless, Cavalier King Charles spaniels did not present higher odds of having 
cardiac remodelling, which implies that although Cavalier King Charles spaniels are more 
predisposed to MMVD, the course of their disease progression is not much different from that 
of other dog breeds. This finding is consistent with previous studies (Borgarelli & Haggstrom, 
2010; Keene et al., 2019). 
Statistically significant differences in age were found between FE and FN dogs and between 
FE and MN dogs. The mean age for the FE group was 8.26 ± 2.96 years, somewhat lower 
than the mean ages for FN (9.41 ± 2.88 years) and MN groups (9.22 ± 2.94 years). Since 
MMVD can affect certain breeds at young ages and since female entire dogs have a higher 
incidence of mammary neoplasia and pyometra is also a rather common disease affecting 
unspayed female dogs (Howe, 2015) – conditions that can be prevented by an 
ovariohysterectomy (Howe, 2015) – it is possible that MMVD was diagnosed before some of 
these dogs were submitted to a spaying procedure, which would explain why the mean age 
for female entire dogs was lower than the mean age for female neutered dogs. A former 
epidemiological study reported a mean age of 4.5 ± 3.2 years for Cavalier King Charles 
spaniels at the time of diagnosis of MMVD, which is consistent with this theory (Chetboul et 
al., 2004). 
Regarding body weight, significant differences were only found between ME and MN dogs (p 
= 0.011). Mean BW was higher in MN (11.97 ± 3.68 kg) than in ME dogs (9.93 ± 3.58 kg). This 
finding is probably related to the fact that neutered dogs tend to gain more weight after 
castration (Howe, 2015).  
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This retrospective study has several limitations. Firstly, the study population in the FE group 
was small compared to the other groups and it is possible that this sample was not 
representative of the FE population. Nonetheless, a small population of FE dogs is something 
that would be expected since spaying is known to help to prevent female dogs to certain 
conditions, as previously mentioned (Howe, 2015). Secondly, some of the dogs included in 
this study were receiving cardiac medical treatment when they were included. Some cardiac 
drugs such as ACEI, spironolactone, and pimobendan can reduce cardiac remodelling, which 
could have affected these cases’ echocardiographic measurements (Bernay et al., 2010; 
Atkins & Haggstrom, 2012; Boswood et al., 2018). Thirdly, fifty-seven English Cocker spaniels 
were included in this study. English Cocker spaniels are known to be predisposed to dilated 
cardiomyopathy, so patients with mild systolic dysfunction secondary to dilated 
cardiomyopathy could have been included (Stern & Meurs, 2017). Nevertheless, since all dogs 
were submitted to a complete echocardiographic examination, it is not likely that these dogs 
could have affected our results. Fourthly, our study population was quite heterogenous, since 
it included dogs that ranged from stage B to stage D according to the staging system proposed 
by the ACVIM consensus panel (Keene, 2019). Fifthly, LA:Ao and LAmax:Ao were used to 
assess left atrial enlargement. Both these ratios are measured in one-dimensional planes and 
since the left atrium enlarges asymmetrically, these are not as accurate as left atrial volumetric 
measurements and three-dimensional echocardiographic measurements and may not reflect 
the atrial absolute size (King et al., 1994; Tidholm, Bodegard-Westling, Hoglund, Ljungvall, & 
Haggstrom, 2011).  
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VII CONCLUSION 
 
Overall this study contributes for a better knowledge of the pathophysiology beneath MMVD in 
dogs, as it demonstrates that neutering status may indeed influence cardiac remodelling in 
MMVD patients and that male entire dogs may be more prone to developing cardiac changes 
secondary to MMVD. 
From another side knowing that: 
• Exogenous testosterone therapy has been associated with thrombotic events in human 
patients (Ruige et al., 2013); 
and that: 
• Testosterone increases platelet receptor density for thromboxane A2 in both humans 
and rats, which promotes platelet aggregation (Ajayi et al., 1995; Glueck et al., 2011); 
it was hypothesized that testosterone in dogs could stimulate platelet aggregation in the 
damaged endothelium of the mitral valve, potentiating the serotonin signal that activates 
valvular interstitial cells, contributing to the pathogenesis of MMVD.  
Hence, it would be interesting to assess testosterone concentrations in a population of male 
dogs with MMVD and compare these changes with their echocardiographic data to investigate 
this hypothesis. 
However, such an assessment is beyond the scope of the present work, but it could be, 
nonetheless, an interesting subject for future investigations. 
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ATTACHMENTS 
 
Table 1. Breed prevalence among 582 dogs diagnosed with MMVD 
 
Breeds Case number (%) 
Airedale 3 (0.52) 
Basset Hound 1 (0.17) 
Beagle 5 (0.86) 
Bearder collie 2 (0.34) 
Bichon Frisé 14 (2.42) 
Border collie 19 (3.28) 
Border terrier 3 (0.52) 
Cairn terrier 6 (1.04) 
Cavalier king charles spaniel 176 (30.4) 
Chihuahua 14 (2.42) 
Chinese crested 1 (0.17) 
Cross breed 85 (14.68) 
Dalmatian 1 (0.17) 
Daschshund 10 (1.73) 
English bull terrier 1 (0.17) 
English Cocker spaniel 57 (9.84) 
English springer spaniel 8 (1.38) 
Fox terrier 3 (0.52) 
Glen of Imaal terrier 1 (0.17) 
Griffon Bruxelois 3 (0.52) 
Hungarian hound 1 (0.17) 
Irish terrier 1 (0.17) 
Italian greyhound 1 (0.17) 
Jack Russel terrier 25 (4.32) 
Japanese Chin 1 (0.17) 
Japanese Spitz 3 (0.52) 
Labrador retriever 1 (0.17) 
Lakeland terrier 1 (0.17) 
Lancashire Heeler 4 (0.69) 
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Table 1. Breed prevalence among 582 dogs diagnosed with MMVD (continuation) 
Lhasa Apso 6 (1.04) 
Lurcher 3 (0.52) 
Maltese 2 (0.34) 
Miniature Poodle 3 (0.52) 
Miniature Schnauzer 20 (3.45) 
Norfolk terrier 2 (0.34) 
Papillon 1 (0.17) 
Parson Russel terrier 1 (0.17) 
Patterdale terrier 1 (0.17) 
Pekingese 2 (0.34) 
Pomeranian 1 (0.17) 
Pug 2 (0.34) 
Scottish terrier 2 (0.34) 
Shetland sheepdog 6 (1.04) 
Shih Tzu 21 (3.63) 
Staffordshire bull terrier 7 (1.21) 
Standard Poodle 1 (0.17) 
Tibetan spaniel 2 (0.34) 
Tibetan terrier 4 (0.69) 
Toy Poodle 3 (0.52) 
West Highland White terrier 16 (2.76) 
Whippet 6 (1.04) 
Yorkshire terrier 19 (3.28) 
Total 582 
 
